Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

This narrowing results from swelling caused by a virus. The respiratory syncytial virus (RSV) causes most bronchiolitis. RSV occurs in epidemics almost every winter. People do not develop life-long ...

This narrowing results from swelling caused by a virus. The respiratory syncytial virus (RSV) causes most bronchiolitis. RSV occurs in epidemics almost every winter. People do not develop life-long ...